Gå til hovedindhold

Friday 24/9

12.00-12.45 Arrival, check-in and pick-up lunch

12.45-13.00 Welcome Steering Committee'

13.00-13.45 Biomarkers in patient failing primary curative therapy, PSA or new markers? Jack Schalken

13.45-14.00 Break

14.00-14.45 The role of modern imagining studies in men with PSA recurrence following curative therapy Stefano Fanti

14.45-15.30 Biochemical recurrence following radical prostatectomy, the role of preoperative risk factors and salvage radiation
Chris Parker

15.30-16.00 Coffee break

16.00-16.45 The role of surgical salvage procedures, salvage lymph-adenectomy and salvage prostatectomy in men with recurrence following radiation therapy
Markus Graefen

16.45-17.00 Break

17.00-18.00 Is salvage procedures needed in all men with biochemi-cal recurrence following curatively intend treatment, the natural history of an increasing PSA and patient selection for salvage procedures
Ola Bratt

18.00-19.00 Own time

19.00-21.00 Dinner

Saturday 25/9

07.00-08.15 Breakfast

08.15-09.00 “The role of adding chemotherapy to standard endocrine therapy in men with PSA recurrence” Andreas Josefsson

09.00-09.45 The role of primary stereotatic radiation in men with newly diagnosed oligometastatic prostate cancer Piet Ost09.45-10.00 Coffee break

10.00-10.45 The role of surgical management of oligo metastatic lesions. Marcus Graefen

10.45-11.30 The role of stereotatic radiation in men with oligometastatic failure following curative therapy Piet Ost

11.30-12.15 Lunch

12.15-13.00 Timing of endocrine therapy following failure of primary curative therapy Jan-Erik Damber

13.00-13.45 Genomic sequencing of metastatic prostate cancer. When, how and what to look for? Henrik Grönberg

13.45-14.15 Concluding remarks and farewell Steering Committee

Clariton Hotel, København